Growth Metrics

Emergent BioSolutions (EBS) Gross Profit (2016 - 2026)

Emergent BioSolutions has reported Gross Profit over the past 16 years, most recently at $84.1 million for Q1 2026.

  • For Q1 2026, Gross Profit fell 37.1% year-over-year to $84.1 million; the TTM value through Mar 2026 reached $367.1 million, down 3.8%, while the annual FY2025 figure was $416.7 million, 15.02% up from the prior year.
  • Gross Profit for Q1 2026 was $84.1 million at Emergent BioSolutions, up from $63.8 million in the prior quarter.
  • Over five years, Gross Profit peaked at $303.9 million in Q1 2022 and troughed at $11.4 million in Q1 2023.
  • A 5-year average of $127.1 million and a median of $139.4 million in 2025 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: tumbled 96.25% in 2023 and later skyrocketed 1266.67% in 2024.
  • Year by year, Gross Profit stood at $162.9 million in 2022, then tumbled by 43.83% to $91.5 million in 2023, then fell by 16.17% to $76.7 million in 2024, then fell by 16.82% to $63.8 million in 2025, then soared by 31.82% to $84.1 million in 2026.
  • Business Quant data shows Gross Profit for EBS at $84.1 million in Q1 2026, $63.8 million in Q4 2025, and $145.2 million in Q3 2025.